Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease
Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease
复制标题
慢性阻塞性肺疾病的血清肌生长抑制素水平和骨骼肌消耗。
DOI：
10.1016/j.rmed.2011.07.016
复制
发表时间：
2012-01-01
影响因子：
4.3
通讯作者：
Chen, Rong-Chang
中科院分区：
文献类型：
--
作者：
Ju, Chun-Rong;Chen, Rong-Chang
简介：已充分证实，肌生长抑制素是骨骼肌质量的负调节剂，并与涉及肌肉萎缩和恶病质的几种疾病有关。骨骼肌萎缩是慢性阻塞性肺疾病（COPD）的重要全身表现，而循环肌生长抑制素在COPD中的表达尚不清楚。本研究的目的是探讨循环肌肉生长抑制素的表达及其与骨骼肌消耗在COPD。方法：71例稳定期COPD患者和60名年龄匹配的健康对照者参加了这项研究。总骨骼肌质量（SMM）的计算根据一个验证的公式，通过使用年龄和人体测量。ELISA法测定血清肌生成抑制素、肿瘤坏死因子（TNF）-α和白细胞介素-6水平。与对照组相比，COPD患者血清肌生长抑制素水平显著升高。（11.85 +/- 4.01）ng/ml vs.（7.46 +/- 2.21）ng/ml，p < 0.01]，而与对照组相比，COPD患者的总SMM显著降低[雄性（20.81 +/- 1.74）kg vs.（27.31 +/- 2.18）kg，雌性（11.70 +/- 0.56）kg vs.（19.89 +/- 1.47）kg]（均p < 0.05）。对所有COPD患者的回归相关分析显示，血清肌生长抑制素水平与SMM无显著相关性，但与TNF-α水平相关（R-2 = 0.042，p = 0.048）。然而，当按性别分层时，血清肌生长抑制素水平与SMM呈负相关，（R-2 = 0.20，p = 0.000）和BMI（R-2 = 0.084，p = 0.019）。这项研究表明，循环肌肉生长抑制素水平在COPD中升高，并与男性患者的SMM相关，提示肌生长抑制素导致COPD中的骨骼肌消耗。(C)2011爱思唯尔有限公司保留所有权利。
Introduction: It is well confirmed that myostatin is a negative regulator of skeletal muscle mass and implicated in several diseases involved in muscle wasting and cachexia. Skeletal muscle wasting is an important systemic manifestation of chronic obstructive pulmonary disease (COPD), while the expression of circulating myostatin in COPD remains unclear. The aim of this study was to investigate the expression of circulating myostatin and its relationship with skeletal muscle wasting in COPD.Methods: Seventy-one patients with stable COPD and sixty age-matched, healthy control subjects participated in the study. Total skeletal muscle mass (SMM) were calculated according to a validated formula by using age and anthropometric measurements. Serum levels of myostatin, tumor necrosis factor (TNF)-alpha and interleukin-6 were determined by ELISA.Results: Serum myostatin levels were significantly elevated in COPD patients when compared to controls [(11.85 +/- 4.01) ng/ml vs. (7.46 +/- 2.21) ng/ml, p < 0.01], while total SMM was significantly decreased in COPD patients when compared to controls [(20.81 +/- 1.74) kg vs. (27.31 +/- 2.18) kg for male, and (11.70 +/- 0.56) kg vs. (19.89 +/- 1.47) kg for female] (both p < 0.05). Regression correlation analysis on all COPD patients showed that serum myostatin levels weren't significantly correlated with SMM, but correlated with TNF-alpha levels (R-2 = 0.042, p = 0.048). However, when stratified for gender, serum myostatin levels were correlated inversely both with SMM (R-2 = 0.20, p = 0.000) and with BMI (R-2 = 0.084, p = 0.019) in subgroup of male patients.Conclusion: This study demonstrates that circulating myostatin levels are elevated in COPD and related to SMM in male patients, suggesting that myostatin contributes to skeletal muscle wasting in COPD. (C) 2011 Elsevier Ltd. All rights reserved.